200+ peer-reviewed articles and other resources illustrate the utility of microsampling technology for a wide variety of analytes and applications.
Watch our step-by-step instructional videos, learn how to correctly use our specimen collection devices to collect samples remotely, and review some of our illustrated Instructions For Use.
Independent groups have published their bioanalytical methods using VAMSTM technology. We've examined those methods and summarized important considerations.
Still Have Questions? Contact Us →
The Mitra device, based on VAMS technology has advantages over DBS cards and filter paper in the areas of collection, processing, and bioanalysis. The Mitra device provides the key benefits of working with dried blood, but with a volumetrically accurate, stable dried blood sample that reduces the incidence of reworks.
Over sixty references prove that Mitra devices are compatible with a wide rage of analytes from therapeutic drugs to DNA/RNA to biomarkers. Download our analyte compatibility list to learn more. If you don't see your analyte of interest contact one of our Microsampling Specialists and they'll be able to help.
Initial implementation requires an upfront investment and may disrupt existing workflow, depending on the current processes in place. However, any initial friction is well worth it - Mitra microsampling technology saves money (e.g. no cold-chain shipping), labor (e.g. compatible with typical liquid handling instrumentation), and resources (e.g use non-clinical staff to collect specimens) over time while better allowing for future growth.
Mitra automation solutions are available that allow medium- and high-throughput labs to process hundreds or thousands of samples per day. Contact a Microsampling Specialist to learn more.
All storage recommendations should follow the specific assay’s stability data as it was validated by the laboratory performing the analysis. Most samples can be stored and shipped at room temperature. Your Microsampling Specialist can offer specialized guidance if needed.
Our customers have produced bridging data showing correlations between venous blood draws and fingerstick blood draws, but there is a dependence on the analytical workflow and the compounds to be analyzed. Different analytes are known to circulate differently in venous and capillary blood, so studies will need to be done for each individual analyte and assay.
These resources provide quick insight into the benefits of of blood microsampling as well as a summary of manuscripts featuring the Mitra® microsampling device powered by VAMS™ technology.
Contact Us
Trajan Scientific Americas Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of blood. They are CE-IVD in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada and Ukraine.
In the USA, Mitra devices are supplied as a Research-Use Only (RUO) product, to assist in method development, other research-related and non-diagnostic activities. Mitra has not been validated for use with any diagnostic testing. The suitability of Mitra for any analytical application must be evaluated and validated by the laboratory or research institute in a manner consistent with local regulatory requirements.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use.
Mitra®, VAMS® & hemaPEN® are registered trademarks owned by entities in the Trajan Group.
Copyright © 2022. All rights reserved.